583 related articles for article (PubMed ID: 19405945)
1. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
4. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
[TBL] [Abstract][Full Text] [Related]
5. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
[TBL] [Abstract][Full Text] [Related]
6. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
7. Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.
Mitrović O; Čokić V; Đikić D; Budeč M; Vignjević S; Subotički T; Gulan M; Radović S; Furtula S
Target Oncol; 2014 Dec; 9(4):367-79. PubMed ID: 24272208
[TBL] [Abstract][Full Text] [Related]
8. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
10. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
11. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
13. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
14. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors for Luminal B-like Breast Cancer.
Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
[TBL] [Abstract][Full Text] [Related]
16. The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast.
Yildirim E; Bektas S; Gundogar O; Findik D; Alcicek S; Erdogan KO; Yildiz M
Anticancer Res; 2020 Oct; 40(10):5649-5657. PubMed ID: 32988889
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
19. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]